Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Takafumi Yanase"'
Autor:
Fukuko Okabe, Shingo Sato, Takafumi Yanase, Takatoshi Higuchi, Kiyohide Komuta, Naoko Morishita, Kunimitsu Kawahara, Hidekazu Suzuki
Publikováno v:
Haigan. 63:15-21
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7c84a2095ac2140073cba6e429fb68f
https://doi.org/10.2482/haigan.63.15
https://doi.org/10.2482/haigan.63.15
Autor:
Satoshi Tanizaki, Kinnosuke Matsumoto, Akihiro Tamiya, Yoshihiko Taniguchi, Yoshinobu Matsuda, Junji Uchida, Kiyonobu Ueno, Hayato Kawachi, Motohiro Tamiya, Takafumi Yanase, Hidekazu Suzuki, Kyoichi Okishio
Purpose Ramucirumab (RAM) and docetaxel (DOC) are commonly used after first-line therapy including immune checkpoint inhibitor (ICI) for advanced non-small cell lung cancer (NSCLC). Therefore, it is important to evaluate sequential strategies of RAM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::008e7ade015b5aac2b04111b3011b487
https://doi.org/10.21203/rs.3.rs-2203249/v1
https://doi.org/10.21203/rs.3.rs-2203249/v1
Autor:
Yoshihiko Taniguchi, Hidekazu Suzuki, Takafumi Yanase, Tomonori Hirashima, Akihiro Tamiya, Motohiro Tamiya, Satoshi Tanizaki, Kinnosuke Matsumoto, Kiyonobu Ueno, Hayato Kawachi, Junji Uchida, Yoshinobu Matsuda, Shinji Atagi
Publikováno v:
Transl Lung Cancer Res
Background Docetaxel (DOC) plus ramucirumab (RAM) has been recommended as an optimal therapy for previously treated patients with non-small cell lung cancer (NSCLC). In a clinical setting, there are few reports about DOC plus RAM, therefore its effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::269dac4e773a743ad47b87db3d72a57e
https://doi.org/10.21037/tlcr-20-1263
https://doi.org/10.21037/tlcr-20-1263
Autor:
Hayato Kawachi, Motohiro Tamiya, Kinnosuke Matsumoto, Akihiro Tamiya, Takafumi Yanase, Satoshi Tanizaki, Toru Kumagai
Publikováno v:
Investigational new drugs. 40(3)
Objective: Ramucirumab plus docetaxel therapy (RAM/DOC) is currently the standard for previously treated advanced non-small cell lung cancer (NSCLC), irrespective of histology. However, the safety data of anti-angiogenic agents for squamous cell NSCL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4589ee5ef9b1b8b3f0ed225bdae619cb
https://pubmed.ncbi.nlm.nih.gov/35024985
https://pubmed.ncbi.nlm.nih.gov/35024985
Autor:
Hidekazu Suzuki, Yoshihiko Taniguchi, Akihiro Tamiya, Hayato Kawachi, Yoshinobu Matsuda, Satoshi Tanizaki, Kinnosuke Matsumoto, Kiyonobu Ueno, Takafumi Yanase, Junji Uchida, Shinji Atagi, Motohiro Tamiya, Yuji Inagaki
Publikováno v:
Journal of geriatric oncology. 13(2)
Ramucirumab (RAM) plus Docetaxel (DOC) is one of the standard treatments after first-line treatment failure in patients with advanced non-small cell lung cancer (NSCLC). However, little is known about the efficacy and safety of RAM plus DOC in older
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c2108a4871b4340c752c2642ab28659
https://pubmed.ncbi.nlm.nih.gov/34602370
https://pubmed.ncbi.nlm.nih.gov/34602370
Autor:
Munenori Kuroyama, Junji Uchida, Kiyonobu Ueno, Satoshi Tanaka, Takafumi Yanase, Takayuki Niitsu, Terumasa Hayashi
Publikováno v:
Nephron. 146(1)
Tyrosine kinase inhibitors (TKIs) that target the epidermal growth factor receptor (EGFR) have shown highly favourable outcomes in patients with advanced-stage non-small-cell lung cancer (NSCLC). The adverse effects of EGFR-TKIs are generally less se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13f44c693cd2a2b6594bdf5c5cfcbb5f
https://pubmed.ncbi.nlm.nih.gov/34569520
https://pubmed.ncbi.nlm.nih.gov/34569520